CA2590696A1

CA2590696A1 - Sustained delivery formulations of octreotide compounds

Sustained delivery formulations of octreotide compounds Download PDF

Info

Publication number: CA2590696A1
Authority: CA; Canada
Prior art keywords: octreotide; day; implant; composition; atrigel
Prior art date: 2004-12-15
Legal status : Abandoned

Application number

CA002590696A

Other languages

English (en)

French (fr)

Inventor

Stephen L. Warren

Eric Dadey

Richard L. Dunn

John Milton Downing

Ellen Qi Li

Current Assignee

Tolmar Therapeutics Inc

Original Assignee

Individual

Priority date

2004-12-15

Filing date

2005-12-15

Publication date

2006-06-22

2005-12-15 Application filed by Individual filed Critical Individual

2006-06-22 Publication of CA2590696A1 publication Critical patent/CA2590696A1/en

Status Abandoned legal-status Critical Current

Links

DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical class C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 title claims abstract description 577
239000000203 mixture Substances 0.000 title claims abstract description 374
238000009472 formulation Methods 0.000 title claims description 135
230000002459 sustained effect Effects 0.000 title description 8
108010016076 Octreotide Proteins 0.000 claims abstract description 578
229960002700 octreotide Drugs 0.000 claims abstract description 457
239000007943 implant Substances 0.000 claims abstract description 185
239000007788 liquid Substances 0.000 claims abstract description 156
230000009969 flowable effect Effects 0.000 claims abstract description 148
229920001169 thermoplastic Polymers 0.000 claims abstract description 112
238000011282 treatment Methods 0.000 claims abstract description 73
239000007787 solid Substances 0.000 claims abstract description 56
102000018997 Growth Hormone Human genes 0.000 claims abstract description 24
108010051696 Growth Hormone Proteins 0.000 claims abstract description 22
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 197
238000000034 method Methods 0.000 claims description 50
229920000728 polyester Polymers 0.000 claims description 50
239000010839 body fluid Substances 0.000 claims description 48
210000001124 body fluid Anatomy 0.000 claims description 46
238000007920 subcutaneous administration Methods 0.000 claims description 32
239000011159 matrix material Substances 0.000 claims description 30
239000004416 thermosoftening plastic Substances 0.000 claims description 28
206010012689 Diabetic retinopathy Diseases 0.000 claims description 26
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 24
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 22
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 20
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
239000012736 aqueous medium Substances 0.000 claims description 16
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
150000002148 esters Chemical class 0.000 claims description 16
229920001577 copolymer Polymers 0.000 claims description 14
239000011148 porous material Substances 0.000 claims description 14
239000002253 acid Substances 0.000 claims description 13
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 13
150000001875 compounds Chemical class 0.000 claims description 13
150000002009 diols Chemical class 0.000 claims description 13
238000011065 in-situ storage Methods 0.000 claims description 13
102000004877 Insulin Human genes 0.000 claims description 12
108090001061 Insulin Proteins 0.000 claims description 12
230000007423 decrease Effects 0.000 claims description 12
JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims description 12
229940125396 insulin Drugs 0.000 claims description 12
238000002156 mixing Methods 0.000 claims description 12
102000051325 Glucagon Human genes 0.000 claims description 11
108060003199 Glucagon Proteins 0.000 claims description 11
208000030533 eye disease Diseases 0.000 claims description 11
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 11
229960004666 glucagon Drugs 0.000 claims description 11
235000013773 glyceryl triacetate Nutrition 0.000 claims description 11
230000002062 proliferating effect Effects 0.000 claims description 11
229960002622 triacetin Drugs 0.000 claims description 11
238000013270 controlled release Methods 0.000 claims description 10
239000001087 glyceryl triacetate Substances 0.000 claims description 10
RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims description 10
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 9
230000001186 cumulative effect Effects 0.000 claims description 9
229920000747 poly(lactic acid) Polymers 0.000 claims description 9
229920001897 terpolymer Polymers 0.000 claims description 9
206010007270 Carcinoid syndrome Diseases 0.000 claims description 8
238000009792 diffusion process Methods 0.000 claims description 8
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 8
206010028980 Neoplasm Diseases 0.000 claims description 7
229920000954 Polyglycolide Polymers 0.000 claims description 7
150000001408 amides Chemical class 0.000 claims description 7
206010012601 diabetes mellitus Diseases 0.000 claims description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
230000017074 necrotic cell death Effects 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 5
229920001610 polycaprolactone Polymers 0.000 claims description 5
108050001286 Somatostatin Receptor Proteins 0.000 claims description 4
150000001991 dicarboxylic acids Chemical class 0.000 claims description 4
239000000539 dimer Substances 0.000 claims description 4
230000003628 erosive effect Effects 0.000 claims description 4
150000002576 ketones Chemical class 0.000 claims description 4
150000007524 organic acids Chemical class 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
102000011096 Somatostatin receptor Human genes 0.000 claims description 3
108010068542 Somatotropin Receptors Proteins 0.000 claims description 3
230000002159 abnormal effect Effects 0.000 claims description 3
150000007513 acids Chemical class 0.000 claims description 3
230000002496 gastric effect Effects 0.000 claims description 3
150000007522 mineralic acids Chemical class 0.000 claims description 3
230000037361 pathway Effects 0.000 claims description 3
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
208000010837 Diabetic eye disease Diseases 0.000 claims description 2
201000011510 cancer Diseases 0.000 claims description 2
239000004632 polycaprolactone Substances 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
206010059245 Angiopathy Diseases 0.000 claims 1
206010011953 Decreased activity Diseases 0.000 claims 1
238000002648 combination therapy Methods 0.000 claims 1
230000002526 effect on cardiovascular system Effects 0.000 claims 1
208000013403 hyperactivity Diseases 0.000 claims 1
238000013268 sustained release Methods 0.000 abstract description 74
239000012730 sustained-release form Substances 0.000 abstract description 74
-1 octreotide compound Chemical class 0.000 abstract description 58
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract description 33
201000010099 disease Diseases 0.000 abstract description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 24
102000005157 Somatostatin Human genes 0.000 abstract description 19
108010056088 Somatostatin Proteins 0.000 abstract description 19
229960000553 somatostatin Drugs 0.000 abstract description 19
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 291
229920000642 polymer Polymers 0.000 description 196
XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 100
238000002347 injection Methods 0.000 description 84
239000007924 injection Substances 0.000 description 84
229960001494 octreotide acetate Drugs 0.000 description 81
210000001519 tissue Anatomy 0.000 description 77
239000003814 drug Substances 0.000 description 75
241000700159 Rattus Species 0.000 description 74
229940079593 drug Drugs 0.000 description 73
238000012360 testing method Methods 0.000 description 70
239000000047 product Substances 0.000 description 64
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
XQEJFZYLWPSJOV-XJQYZYIXSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosa Chemical compound CC(O)=O.C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 XQEJFZYLWPSJOV-XJQYZYIXSA-N 0.000 description 62
108700014314 sandostatinLAR Proteins 0.000 description 62
239000000243 solution Substances 0.000 description 60
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 48
102000013275 Somatomedins Human genes 0.000 description 47
229940066741 octreotide 20 mg Drugs 0.000 description 46
241001465754 Metazoa Species 0.000 description 45
241000283973 Oryctolagus cuniculus Species 0.000 description 44
229940072272 sandostatin Drugs 0.000 description 38
230000036470 plasma concentration Effects 0.000 description 36
239000000499 gel Substances 0.000 description 33
239000000178 monomer Substances 0.000 description 30
239000000126 substance Substances 0.000 description 29
238000006243 chemical reaction Methods 0.000 description 27
238000002360 preparation method Methods 0.000 description 27
238000004458 analytical method Methods 0.000 description 26
210000004369 blood Anatomy 0.000 description 26
239000008280 blood Substances 0.000 description 26
206010015150 Erythema Diseases 0.000 description 25
239000003607 modifier Substances 0.000 description 25
230000003285 pharmacodynamic effect Effects 0.000 description 25
238000010254 subcutaneous injection Methods 0.000 description 23
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 22
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
239000000463 material Substances 0.000 description 21
238000004007 reversed phase HPLC Methods 0.000 description 20
239000002904 solvent Substances 0.000 description 19
239000007929 subcutaneous injection Substances 0.000 description 19
210000002966 serum Anatomy 0.000 description 18
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 17
206010012735 Diarrhoea Diseases 0.000 description 17
230000003247 decreasing effect Effects 0.000 description 17
230000007794 irritation Effects 0.000 description 17
230000000694 effects Effects 0.000 description 16
150000003077 polyols Chemical class 0.000 description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
238000012754 cardiac puncture Methods 0.000 description 15
231100000321 erythema Toxicity 0.000 description 15
229920005862 polyol Polymers 0.000 description 15
230000001225 therapeutic effect Effects 0.000 description 15
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
XQEJFZYLWPSJOV-UHFFFAOYSA-N acetic acid;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-n-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide Chemical compound CC(O)=O.O=C1NC(CC=2C=CC=CC=2)C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(C(=O)NC(CO)C(O)C)CSSCC1NC(=O)C(N)CC1=CC=CC=C1 XQEJFZYLWPSJOV-UHFFFAOYSA-N 0.000 description 14
150000001413 amino acids Chemical class 0.000 description 14
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 14
239000008103 glucose Substances 0.000 description 14
239000004014 plasticizer Substances 0.000 description 14
239000011550 stock solution Substances 0.000 description 14
238000005303 weighing Methods 0.000 description 14
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
229940024606 amino acid Drugs 0.000 description 13
235000001014 amino acid Nutrition 0.000 description 13
239000000122 growth hormone Substances 0.000 description 13
108090000765 processed proteins & peptides Proteins 0.000 description 13
229940075620 somatostatin analogue Drugs 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
102000011923 Thyrotropin Human genes 0.000 description 12
108010061174 Thyrotropin Proteins 0.000 description 12
230000002411 adverse Effects 0.000 description 12
235000014113 dietary fatty acids Nutrition 0.000 description 12
239000000194 fatty acid Substances 0.000 description 12
229930195729 fatty acid Natural products 0.000 description 12
125000005647 linker group Chemical group 0.000 description 12
206010000599 Acromegaly Diseases 0.000 description 11
230000008569 process Effects 0.000 description 11
231100000419 toxicity Toxicity 0.000 description 11
230000001988 toxicity Effects 0.000 description 11
150000001298 alcohols Chemical class 0.000 description 10
230000006870 function Effects 0.000 description 10
125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
230000005856 abnormality Effects 0.000 description 9
230000015556 catabolic process Effects 0.000 description 9
125000004122 cyclic group Chemical group 0.000 description 9
238000012377 drug delivery Methods 0.000 description 9
235000011187 glycerol Nutrition 0.000 description 9
208000034656 Contusions Diseases 0.000 description 8
JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 8
102400000015 Vasoactive intestinal peptide Human genes 0.000 description 8
238000006065 biodegradation reaction Methods 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
150000001720 carbohydrates Chemical class 0.000 description 8
238000006731 degradation reaction Methods 0.000 description 8
LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
125000000524 functional group Chemical group 0.000 description 8
210000000232 gallbladder Anatomy 0.000 description 8
230000002209 hydrophobic effect Effects 0.000 description 8
238000010255 intramuscular injection Methods 0.000 description 8
239000007927 intramuscular injection Substances 0.000 description 8
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 8
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 8
230000004393 visual impairment Effects 0.000 description 8
201000004569 Blindness Diseases 0.000 description 7
208000032843 Hemorrhage Diseases 0.000 description 7
206010068115 Metastatic carcinoid tumour Diseases 0.000 description 7
150000004665 fatty acids Chemical class 0.000 description 7
238000004128 high performance liquid chromatography Methods 0.000 description 7
239000004615 ingredient Substances 0.000 description 7
238000007918 intramuscular administration Methods 0.000 description 7
238000002955 isolation Methods 0.000 description 7
238000011068 loading method Methods 0.000 description 7
208000002780 macular degeneration Diseases 0.000 description 7
210000000115 thoracic cavity Anatomy 0.000 description 7
YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
208000001344 Macular Edema Diseases 0.000 description 6
UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 6
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 6
206010064930 age-related macular degeneration Diseases 0.000 description 6
239000000969 carrier Substances 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
238000004949 mass spectrometry Methods 0.000 description 6
230000004060 metabolic process Effects 0.000 description 6
239000004005 microsphere Substances 0.000 description 6
238000012986 modification Methods 0.000 description 6
238000002428 photodynamic therapy Methods 0.000 description 6
239000003880 polar aprotic solvent Substances 0.000 description 6
229920001223 polyethylene glycol Polymers 0.000 description 6
238000006116 polymerization reaction Methods 0.000 description 6
238000001556 precipitation Methods 0.000 description 6
239000000600 sorbitol Substances 0.000 description 6
235000010356 sorbitol Nutrition 0.000 description 6
230000008961 swelling Effects 0.000 description 6
239000001069 triethyl citrate Substances 0.000 description 6
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 6
235000013769 triethyl citrate Nutrition 0.000 description 6
238000002604 ultrasonography Methods 0.000 description 6
229960003895 verteporfin Drugs 0.000 description 6
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
206010002091 Anaesthesia Diseases 0.000 description 5
208000005590 Choroidal Neovascularization Diseases 0.000 description 5
206010060823 Choroidal neovascularisation Diseases 0.000 description 5
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 5
206010025415 Macular oedema Diseases 0.000 description 5
206010028851 Necrosis Diseases 0.000 description 5
206010029113 Neovascularisation Diseases 0.000 description 5
208000022873 Ocular disease Diseases 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 5
206010038934 Retinopathy proliferative Diseases 0.000 description 5
206010039509 Scab Diseases 0.000 description 5
206010042674 Swelling Diseases 0.000 description 5
XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 5
208000009311 VIPoma Diseases 0.000 description 5
239000000654 additive Substances 0.000 description 5
230000037005 anaesthesia Effects 0.000 description 5
201000007917 background diabetic retinopathy Diseases 0.000 description 5
230000008901 benefit Effects 0.000 description 5
208000034158 bleeding Diseases 0.000 description 5
230000000740 bleeding effect Effects 0.000 description 5
230000036765 blood level Effects 0.000 description 5
210000004204 blood vessel Anatomy 0.000 description 5
230000037396 body weight Effects 0.000 description 5
230000008859 change Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
230000015271 coagulation Effects 0.000 description 5
238000005345 coagulation Methods 0.000 description 5
208000028659 discharge Diseases 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
238000013401 experimental design Methods 0.000 description 5
238000001125 extrusion Methods 0.000 description 5
230000003301 hydrolyzing effect Effects 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
229960002725 isoflurane Drugs 0.000 description 5
230000003902 lesion Effects 0.000 description 5
201000010230 macular retinal edema Diseases 0.000 description 5
230000004048 modification Effects 0.000 description 5
150000002894 organic compounds Chemical class 0.000 description 5
239000003960 organic solvent Substances 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
208000012802 recumbency Diseases 0.000 description 5
230000037390 scarring Effects 0.000 description 5
XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 4
OMIHCBSQSYMFDP-UHFFFAOYSA-N 3-hydroxy-5-methoxy-3-methoxycarbonyl-5-oxopentanoic acid Chemical compound COC(=O)CC(O)(CC(O)=O)C(=O)OC OMIHCBSQSYMFDP-UHFFFAOYSA-N 0.000 description 4
YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
208000007135 Retinal Neovascularization Diseases 0.000 description 4
ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 4
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
208000000208 Wet Macular Degeneration Diseases 0.000 description 4
125000001931 aliphatic group Chemical group 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 4
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
239000012867 bioactive agent Substances 0.000 description 4
229920002988 biodegradable polymer Polymers 0.000 description 4
239000004621 biodegradable polymer Substances 0.000 description 4
210000000476 body water Anatomy 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000005352 clarification Methods 0.000 description 4
230000001276 controlling effect Effects 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
238000009826 distribution Methods 0.000 description 4
239000013583 drug formulation Substances 0.000 description 4
238000002565 electrocardiography Methods 0.000 description 4
239000003995 emulsifying agent Substances 0.000 description 4
TVQGDYNRXLTQAP-UHFFFAOYSA-N ethyl heptanoate Chemical compound CCCCCCC(=O)OCC TVQGDYNRXLTQAP-UHFFFAOYSA-N 0.000 description 4
229940116333 ethyl lactate Drugs 0.000 description 4
230000004438 eyesight Effects 0.000 description 4
229960001031 glucose Drugs 0.000 description 4
229940074076 glycerol formal Drugs 0.000 description 4
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 4
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 4
238000002430 laser surgery Methods 0.000 description 4
238000007433 macroscopic evaluation Methods 0.000 description 4
239000011859 microparticle Substances 0.000 description 4
206010028320 muscle necrosis Diseases 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
201000007914 proliferative diabetic retinopathy Diseases 0.000 description 4
238000012216 screening Methods 0.000 description 4
RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 4
HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 4
230000001629 suppression Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
150000003628 tricarboxylic acids Chemical class 0.000 description 4
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 3
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 3
101000942694 Bos taurus Clusterin Proteins 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 3
UDSFAEKRVUSQDD-UHFFFAOYSA-N Dimethyl adipate Chemical compound COC(=O)CCCCC(=O)OC UDSFAEKRVUSQDD-UHFFFAOYSA-N 0.000 description 3
MUXOBHXGJLMRAB-UHFFFAOYSA-N Dimethyl succinate Chemical compound COC(=O)CCC(=O)OC MUXOBHXGJLMRAB-UHFFFAOYSA-N 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
102000009151 Luteinizing Hormone Human genes 0.000 description 3
108010073521 Luteinizing Hormone Proteins 0.000 description 3
LOMVENUNSWAXEN-UHFFFAOYSA-N Methyl oxalate Chemical compound COC(=O)C(=O)OC LOMVENUNSWAXEN-UHFFFAOYSA-N 0.000 description 3
239000004952 Polyamide Substances 0.000 description 3
206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 description 3
208000017442 Retinal disease Diseases 0.000 description 3
206010038923 Retinopathy Diseases 0.000 description 3
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 3
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
208000038016 acute inflammation Diseases 0.000 description 3
230000006022 acute inflammation Effects 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
125000005233 alkylalcohol group Chemical group 0.000 description 3
230000002862 amidating effect Effects 0.000 description 3
238000000540 analysis of variance Methods 0.000 description 3
239000002870 angiogenesis inducing agent Substances 0.000 description 3
150000008064 anhydrides Chemical group 0.000 description 3
230000001772 anti-angiogenic effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
125000003710 aryl alkyl group Chemical group 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
201000001883 cholelithiasis Diseases 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
230000002124 endocrine Effects 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
150000002170 ethers Chemical class 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
238000013265 extended release Methods 0.000 description 3
150000002191 fatty alcohols Chemical class 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
229920001519 homopolymer Polymers 0.000 description 3
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000008595 infiltration Effects 0.000 description 3
238000001764 infiltration Methods 0.000 description 3
238000009533 lab test Methods 0.000 description 3
239000004310 lactic acid Substances 0.000 description 3
235000014655 lactic acid Nutrition 0.000 description 3
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 3
238000002386 leaching Methods 0.000 description 3
238000004811 liquid chromatography Methods 0.000 description 3
230000003448 neutrophilic effect Effects 0.000 description 3
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
230000036407 pain Effects 0.000 description 3
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
229920002647 polyamide Polymers 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000002207 retinal effect Effects 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
238000007711 solidification Methods 0.000 description 3
239000011877 solvent mixture Substances 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
229940034208 thyroxine Drugs 0.000 description 3
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 3
230000009466 transformation Effects 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
150000004072 triols Chemical class 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
GFAZGHREJPXDMH-UHFFFAOYSA-N 1,3-dipalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCC GFAZGHREJPXDMH-UHFFFAOYSA-N 0.000 description 2
HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
208000005598 Angioid Streaks Diseases 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000033825 Chorioretinal atrophy Diseases 0.000 description 2
DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 2
NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
206010062767 Hypophysitis Diseases 0.000 description 2
206010022095 Injection Site reaction Diseases 0.000 description 2
206010022061 Injection site erythema Diseases 0.000 description 2
206010057880 Injection site nodule Diseases 0.000 description 2
102100037852 Insulin-like growth factor I Human genes 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000029549 Muscle injury Diseases 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
206010030210 Oesophageal varices haemorrhage Diseases 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
206010033645 Pancreatitis Diseases 0.000 description 2
229920002732 Polyanhydride Polymers 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
206010038848 Retinal detachment Diseases 0.000 description 2
102000004117 Somatostatin receptor 3 Human genes 0.000 description 2
108090000674 Somatostatin receptor 3 Proteins 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229930182558 Sterol Natural products 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
208000033809 Suppuration Diseases 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
IHNHAHWGVLXCCI-CYDGBPFRSA-N [(2s,3s,4s,5r)-3,4,5-triacetyloxyoxolan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1O[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O IHNHAHWGVLXCCI-CYDGBPFRSA-N 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
206010000059 abdominal discomfort Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical group OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
210000000577 adipose tissue Anatomy 0.000 description 2
125000005907 alkyl ester group Chemical group 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
239000004037 angiogenesis inhibitor Substances 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
229960002903 benzyl benzoate Drugs 0.000 description 2
LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
230000031018 biological processes and functions Effects 0.000 description 2
OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 2
210000001217 buttock Anatomy 0.000 description 2
229930188620 butyrolactone Natural products 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
125000005587 carbonate group Chemical group 0.000 description 2
229940106189 ceramide Drugs 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
230000009137 competitive binding Effects 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
230000000593 degrading effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 2
208000024170 esophageal varices Diseases 0.000 description 2
201000010120 esophageal varix Diseases 0.000 description 2
125000004185 ester group Chemical group 0.000 description 2
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
229940093471 ethyl oleate Drugs 0.000 description 2
210000000416 exudates and transudate Anatomy 0.000 description 2
230000003328 fibroblastic effect Effects 0.000 description 2
238000011049 filling Methods 0.000 description 2
206010016766 flatulence Diseases 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000011010 flushing procedure Methods 0.000 description 2
238000001879 gelation Methods 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
125000001072 heteroaryl group Chemical group 0.000 description 2
229920006158 high molecular weight polymer Polymers 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
150000002596 lactones Chemical class 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
208000018769 loss of vision Diseases 0.000 description 2
231100000864 loss of vision Toxicity 0.000 description 2
229940040129 luteinizing hormone Drugs 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001814 pectin Substances 0.000 description 2
235000010987 pectin Nutrition 0.000 description 2
229920001277 pectin Polymers 0.000 description 2
FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
230000000649 photocoagulation Effects 0.000 description 2
210000003635 pituitary gland Anatomy 0.000 description 2
229920001281 polyalkylene Polymers 0.000 description 2
229920000515 polycarbonate Polymers 0.000 description 2
239000004417 polycarbonate Substances 0.000 description 2
229920001855 polyketal Polymers 0.000 description 2
239000004626 polylactic acid Substances 0.000 description 2
229920002959 polymer blend Polymers 0.000 description 2
229920006324 polyoxymethylene Polymers 0.000 description 2
229920002635 polyurethane Polymers 0.000 description 2
239000004814 polyurethane Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000036387 respiratory rate Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
210000001525 retina Anatomy 0.000 description 2
230000004264 retinal detachment Effects 0.000 description 2
210000001210 retinal vessel Anatomy 0.000 description 2
238000007151 ring opening polymerisation reaction Methods 0.000 description 2
238000005185 salting out Methods 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
235000021309 simple sugar Nutrition 0.000 description 2
230000000391 smoking effect Effects 0.000 description 2
230000008023 solidification Effects 0.000 description 2
230000003381 solubilizing effect Effects 0.000 description 2
241000894007 species Species 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000013179 statistical model Methods 0.000 description 2
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
150000003432 sterols Chemical class 0.000 description 2
235000003702 sterols Nutrition 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
201000009032 substance abuse Diseases 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
230000032258 transport Effects 0.000 description 2
150000003627 tricarboxylic acid derivatives Chemical class 0.000 description 2
DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
238000002562 urinalysis Methods 0.000 description 2
230000002792 vascular Effects 0.000 description 2
230000024883 vasodilation Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
CQYBNXGHMBNGCG-FXQIFTODSA-N (2s,3as,7as)-2,3,3a,4,5,6,7,7a-octahydro-1h-indol-1-ium-2-carboxylate Chemical compound C1CCC[C@@H]2[NH2+][C@H](C(=O)[O-])C[C@@H]21 CQYBNXGHMBNGCG-FXQIFTODSA-N 0.000 description 1
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17beta-estradiol Natural products OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
BEUIKSKUMFAMGT-UHFFFAOYSA-N 1h-indole;1,3-thiazole Chemical compound C1=CSC=N1.C1=CC=C2NC=CC2=C1 BEUIKSKUMFAMGT-UHFFFAOYSA-N 0.000 description 1
FMKIFJLNOGNQJR-UHFFFAOYSA-N 2,3-dihydroxypropyl tridec-2-enoate Chemical compound CCCCCCCCCCC=CC(=O)OCC(O)CO FMKIFJLNOGNQJR-UHFFFAOYSA-N 0.000 description 1
JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical group FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 1
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
229940093475 2-ethoxyethanol Drugs 0.000 description 1
SVONRAPFKPVNKG-UHFFFAOYSA-N 2-ethoxyethyl acetate Chemical compound CCOCCOC(C)=O SVONRAPFKPVNKG-UHFFFAOYSA-N 0.000 description 1
FQRHOOHLUYHMGG-BTJKTKAUSA-N 3-(2-acetylphenothiazin-10-yl)propyl-dimethylazanium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C/C(O)=O.C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 FQRHOOHLUYHMGG-BTJKTKAUSA-N 0.000 description 1
BXRLWGXPSRYJDZ-UHFFFAOYSA-N 3-cyanoalanine Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 description 1
JDRMYOQETPMYQX-UHFFFAOYSA-M 4-methoxy-4-oxobutanoate Chemical compound COC(=O)CCC([O-])=O JDRMYOQETPMYQX-UHFFFAOYSA-M 0.000 description 1
LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
LPEKGGXMPWTOCB-UHFFFAOYSA-N 8beta-(2,3-epoxy-2-methylbutyryloxy)-14-acetoxytithifolin Natural products COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 1
206010000060 Abdominal distension Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000003200 Adenoma Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
108010082126 Alanine transaminase Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
BCFCRXOJOFDUMZ-ONKRVSLGSA-N Anecortave Chemical compound O=C1CC[C@]2(C)C3=CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 BCFCRXOJOFDUMZ-ONKRVSLGSA-N 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
208000027496 Behcet disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000011632 Caseins Human genes 0.000 description 1
108010076119 Caseins Proteins 0.000 description 1
208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
239000004970 Chain extender Substances 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010008790 Choroidal rupture Diseases 0.000 description 1
208000002691 Choroiditis Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
206010058202 Cystoid macular oedema Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
206010012655 Diabetic complications Diseases 0.000 description 1
206010012688 Diabetic retinal oedema Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
201000000628 Gas Gangrene Diseases 0.000 description 1
102400000921 Gastrin Human genes 0.000 description 1
108010052343 Gastrins Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
239000004348 Glyceryl diacetate Substances 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
102100020948 Growth hormone receptor Human genes 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020850 Hyperthyroidism Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
101150088952 IGF1 gene Proteins 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
201000000512 Intraocular Lymphoma Diseases 0.000 description 1
206010022941 Iridocyclitis Diseases 0.000 description 1
208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
DGYHPLMPMRKMPD-UHFFFAOYSA-N L-propargyl glycine Natural products OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
206010025412 Macular dystrophy congenital Diseases 0.000 description 1
206010025476 Malabsorption Diseases 0.000 description 1
208000004155 Malabsorption Syndromes Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102400001357 Motilin Human genes 0.000 description 1
101800002372 Motilin Proteins 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
101100074988 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nmp-1 gene Proteins 0.000 description 1
BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
208000003435 Optic Neuritis Diseases 0.000 description 1
206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
208000034038 Pathologic Neovascularization Diseases 0.000 description 1
206010073286 Pathologic myopia Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000005888 Periodontal Pocket Diseases 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
229930182556 Polyacetal Natural products 0.000 description 1
229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
229920002396 Polyurea Polymers 0.000 description 1
208000003971 Posterior uveitis Diseases 0.000 description 1
208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
201000002154 Pterygium Diseases 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
208000037111 Retinal Hemorrhage Diseases 0.000 description 1
206010052643 Retinal coloboma Diseases 0.000 description 1
208000007014 Retinitis pigmentosa Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
206010038933 Retinopathy of prematurity Diseases 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
108010086019 Secretin Proteins 0.000 description 1
102100037505 Secretin Human genes 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000014286 Serpiginous choroiditis Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
208000024799 Thyroid disease Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
206010047555 Visual field defect Diseases 0.000 description 1
208000034698 Vitreous haemorrhage Diseases 0.000 description 1
206010063942 Vitreous loss Diseases 0.000 description 1
208000029977 White Dot Syndromes Diseases 0.000 description 1
IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 1
ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960001946 acepromazine maleate Drugs 0.000 description 1
125000004036 acetal group Chemical group 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
159000000021 acetate salts Chemical class 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000001361 adipic acid Chemical group 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
IVHKZGYFKJRXBD-UHFFFAOYSA-N amino carbamate Chemical compound NOC(N)=O IVHKZGYFKJRXBD-UHFFFAOYSA-N 0.000 description 1
229960001232 anecortave Drugs 0.000 description 1
230000000964 angiostatic effect Effects 0.000 description 1
201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
201000004612 anterior uveitis Diseases 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
150000008430 aromatic amides Chemical class 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
229940118398 atridox Drugs 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
229940120638 avastin Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
206010072959 birdshot chorioretinopathy Diseases 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004155 blood-retinal barrier Anatomy 0.000 description 1
230000004378 blood-retinal barrier Effects 0.000 description 1
JDRMYOQETPMYQX-UHFFFAOYSA-N butanedioic acid monomethyl ester Natural products COC(=O)CCC(O)=O JDRMYOQETPMYQX-UHFFFAOYSA-N 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
MMCOUVMKNAHQOY-UHFFFAOYSA-N carbonoperoxoic acid Chemical compound OOC(O)=O MMCOUVMKNAHQOY-UHFFFAOYSA-N 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
150000001783 ceramides Chemical class 0.000 description 1
229940082500 cetostearyl alcohol Drugs 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
229940074979 cetyl palmitate Drugs 0.000 description 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000001112 coagulating effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000001427 coherent effect Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000013329 compounding Methods 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
201000010206 cystoid macular edema Diseases 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229950006137 dexfosfoserine Drugs 0.000 description 1
201000011190 diabetic macular edema Diseases 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
125000001142 dicarboxylic acid group Chemical group 0.000 description 1
FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
229960001826 dimethylphthalate Drugs 0.000 description 1
SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
229960001172 doxycycline hyclate Drugs 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
230000003826 endocrine responses Effects 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
ISVXIZFUEUVXPG-UHFFFAOYSA-N etiopurpurin Chemical compound CC1C2(CC)C(C(=O)OCC)=CC(C3=NC(C(=C3C)CC)=C3)=C2N=C1C=C(N1)C(CC)=C(C)C1=CC1=C(CC)C(C)=C3N1 ISVXIZFUEUVXPG-UHFFFAOYSA-N 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000014101 glucose homeostasis Effects 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
230000036252 glycation Effects 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229940055390 glycerin / propylene glycol Drugs 0.000 description 1
235000019443 glyceryl diacetate Nutrition 0.000 description 1
229940068939 glyceryl monolaurate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
150000002339 glycosphingolipids Chemical class 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000003128 head Anatomy 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
150000002390 heteroarenes Chemical class 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000002433 hydrophilic molecules Chemical class 0.000 description 1
150000001261 hydroxy acids Chemical class 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
238000010983 kinetics study Methods 0.000 description 1
238000011545 laboratory measurement Methods 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229940099367 lanolin alcohols Drugs 0.000 description 1
238000013532 laser treatment Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229940076783 lucentis Drugs 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229940092110 macugen Drugs 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000845 maltitol Substances 0.000 description 1
235000010449 maltitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
229940035436 maltitol Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229940127554 medical product Drugs 0.000 description 1
238000002483 medication Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
229940057867 methyl lactate Drugs 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Chemical group OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
150000002772 monosaccharides Chemical group 0.000 description 1
SWYVHBPXKKDGLL-UHFFFAOYSA-N n,n,3-trimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(C)=C1 SWYVHBPXKKDGLL-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
201000011519 neuroendocrine tumor Diseases 0.000 description 1
VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
WVJVHUWVQNLPCR-UHFFFAOYSA-N octadecanoyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCC WVJVHUWVQNLPCR-UHFFFAOYSA-N 0.000 description 1
DEQANNDTNATYII-RRCPSWKPSA-N octreotide Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-RRCPSWKPSA-N 0.000 description 1
VOXZDWNPVJITMN-WKUFJEKOSA-N oestradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-WKUFJEKOSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000003901 oxalic acid esters Chemical class 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000012466 permeate Substances 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
230000002165 photosensitisation Effects 0.000 description 1
239000003504 photosensitizing agent Substances 0.000 description 1
231100000760 phototoxic Toxicity 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
229920000218 poly(hydroxyvalerate) Polymers 0.000 description 1
229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
238000006068 polycondensation reaction Methods 0.000 description 1
239000000622 polydioxanone Substances 0.000 description 1
229920006149 polyester-amide block copolymer Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000000275 quality assurance Methods 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
238000007142 ring opening reaction Methods 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
229960002101 secretin Drugs 0.000 description 1
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
231100000004 severe toxicity Toxicity 0.000 description 1
238000010008 shearing Methods 0.000 description 1
KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
102000004115 somatostatin receptor 5 Human genes 0.000 description 1
108090000680 somatostatin receptor 5 Proteins 0.000 description 1
230000003294 somatostatinlike Effects 0.000 description 1
235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
239000001570 sorbitan monopalmitate Substances 0.000 description 1
229940031953 sorbitan monopalmitate Drugs 0.000 description 1
235000011078 sorbitan tristearate Nutrition 0.000 description 1
239000001589 sorbitan tristearate Substances 0.000 description 1
229960004129 sorbitan tristearate Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
229950001248 squalamine Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000003068 static effect Effects 0.000 description 1
DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
229940032091 stigmasterol Drugs 0.000 description 1
HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
235000016831 stigmasterol Nutrition 0.000 description 1
BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
150000001420 substituted heterocyclic compounds Chemical class 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000003900 succinic acid esters Chemical class 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
238000009121 systemic therapy Methods 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
150000000000 tetracarboxylic acids Chemical class 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
229920001187 thermosetting polymer Polymers 0.000 description 1
208000021510 thyroid gland disease Diseases 0.000 description 1
238000012090 tissue culture technique Methods 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
231100000607 toxicokinetics Toxicity 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
239000013638 trimer Substances 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
208000022810 undifferentiated (embryonal) sarcoma Diseases 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000004304 visual acuity Effects 0.000 description 1
229940061392 visudyne Drugs 0.000 description 1
201000007790 vitelliform macular dystrophy Diseases 0.000 description 1